Rituxan
E46089
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
All labels observed (5)
| Label | Occurrences |
|---|---|
| rituximab | 10 |
| Rituxan canonical | 5 |
| Ocrevus | 1 |
| Truxima | 1 |
| obinutuzumab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T363284 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Rituxan Context triple: [Genentech, notableProduct, Rituxan]
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Rituxan Target entity description: Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
C.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
Statements (52)
| Predicate | Object |
|---|---|
| instanceOf |
CD20-directed cytolytic antibody
ⓘ
biologic drug ⓘ chimeric monoclonal antibody ⓘ monoclonal antibody ⓘ |
| ATCCode | L01FA01 ⓘ |
| combinationRegimen | R-CHOP ⓘ |
| commonAdverseEffect |
chills
ⓘ
fever ⓘ infections ⓘ infusion-related reactions ⓘ neutropenia ⓘ |
| contraindicatedIn | known severe hypersensitivity to rituximab ⓘ |
| developedBy |
Biogen
ⓘ
Genentech ⓘ |
| firstApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| firstApprovedYear | 1997 ⓘ |
| hasBiosimilar |
Riabni
ⓘ
Ruxience ⓘ Rituxan self-linksurface differs ⓘ
surface form:
Truxima
|
| hasBlackBoxWarning |
hepatitis B virus reactivation
ⓘ
infusion reactions ⓘ progressive multifocal leukoencephalopathy ⓘ severe mucocutaneous reactions ⓘ |
| hasDrugClass |
antineoplastic agent
ⓘ
immunosuppressive agent ⓘ |
| hasGenericName | rituximab ⓘ |
| hasINN |
Rituxan
self-linksurface differs
ⓘ
surface form:
rituximab
|
| hasMoleculeType | IgG1 kappa monoclonal antibody ⓘ |
| indicatedFor |
chronic lymphocytic leukemia
ⓘ
diffuse large B-cell lymphoma ⓘ follicular lymphoma ⓘ granulomatosis with polyangiitis ⓘ microscopic polyangiitis ⓘ non-Hodgkin lymphoma ⓘ pemphigus vulgaris ⓘ rheumatoid arthritis ⓘ |
| isChimericOf |
human antibody
ⓘ
mouse antibody ⓘ |
| marketedBy |
Biogen
ⓘ
Genentech ⓘ |
| mechanismOfAction |
binds CD20 on B cells
ⓘ
induces B-cell lysis ⓘ induces apoptosis of B cells ⓘ mediates antibody-dependent cellular cytotoxicity ⓘ mediates complement-dependent cytotoxicity ⓘ |
| oftenUsedWith |
cyclophosphamide
ⓘ
doxorubicin ⓘ prednisone ⓘ vincristine ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
B lymphocytes
ⓘ
CD20 protein ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Rituxan Description of subject: Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
Referenced by (18)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Truxima
this entity surface form:
rituximab
this entity surface form:
rituximab
this entity surface form:
rituximab
this entity surface form:
rituximab
this entity surface form:
obinutuzumab
this entity surface form:
rituximab
this entity surface form:
rituximab
this entity surface form:
rituximab
this entity surface form:
rituximab